PetVivo Holdings, Inc. PETV

What this company does

The Company has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of ten issued patents (consisting of six U.S. patents and four foreign patents), two U.S. patent applications, and six proprietary trade secrets protects the Company’s biomaterials, products, production processes and methods of use. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses, in the second quarter of its fiscal year ended March 31, 2022. In connection with the Public Offering, the Company’s common stock and warrants were registered under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market, LLC under the symbols “PETV” and “PETVW,” respectively. The Company operates as one segment from its corporate headquarters in Edina, Minnesota. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals such as cats, dogs and horses.

Written from the business description in PetVivo Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.